Cargando…
CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells
The failure of a long-lasting curative therapeutic benefit of currently applied chemotherapies against malignant cancers is suggested to be caused by the ineffectiveness of such interventions on cancer stem cells (CSCs). CD133/AC133 is a cell surface protein previously shown to have potential to ide...
Autores principales: | Poonaki, Elham, Nickel, Ann-Christin, Shafiee Ardestani, Mehdi, Rademacher, Lars, Kaul, Marilyn, Apartsin, Evgeny, Meuth, Sven G., Gorji, Ali, Janiak, Christoph, Kahlert, Ulf Dietrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141725/ https://www.ncbi.nlm.nih.gov/pubmed/35628289 http://dx.doi.org/10.3390/ijms23105479 |
Ejemplares similares
-
Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery
por: Giesen, Beatriz, et al.
Publicado: (2021) -
PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023) -
The role of the ZEB1–neuroinflammation axis in CNS disorders
por: Poonaki, Elham, et al.
Publicado: (2022) -
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
por: Thompson, Ravyn M., et al.
Publicado: (2017) -
Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines
por: De los Santos-Jiménez, Juan, et al.
Publicado: (2023)